Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Immunomodulation for improving long-term outcomes in myeloma

Michel Delforge • 18 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Bortezomib CAR-T Carfilzomib Daratumumab Elotuzumab Isatuximab Lenalidomide Thalidomide

Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses immunomodulation as a foundation for improving long-term outcomes in newly diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Michel Delforge

2:20
HRQoL in heavily pretreated patients with MM treated with ide-cel or standard regimens in KarMMa-3
Michel Delforge • 10 Dec 2023
2:16
Moving CAR-T therapy into the frontline setting in myeloma: insights into CARTITUDE-5 & CARTITUDE-6
Michel Delforge • 4 Oct 2023
1:50
How might inequalities in access to CAR-T therapy for multiple myeloma be addressed?
Michel Delforge • 4 Oct 2023
8:28
Treatment selection for patients with multiple myeloma at first relapse and beyond
Michel Delforge • 4 Oct 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals